Gastric retention pellets of edaravone with enhanced oral bioavailability::Absorption mechanism, development, and in vitro/in vivo evaluation by Li, Qingguo et al.
 
 
Gastric retention pellets of edaravone with
enhanced oral bioavailability:
Li, Qingguo; Huang, Wenhai; Yang, Juan; Wang, Jianfeng; Hu, Min; Mo, Jianmei; Cheng,




Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Li, Q, Huang, W, Yang, J, Wang, J, Hu, M, Mo, J, Cheng, Y, Ou, Z, Zhang, Z & Guan, S 2018, 'Gastric retention
pellets of edaravone with enhanced oral bioavailability: Absorption mechanism, development, and in vitro/in vivo
evaluation' European Journal of Pharmaceutical Science, vol. 119, pp. 62-69.
https://doi.org/10.1016/j.ejps.2018.04.002
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 13. Aug. 2019
Accepted Manuscript
Gastric retention pellets of edaravone with enhanced oral
bioavailability: Absorption mechanism, development, and in
vitro/in vivo evaluation
Qingguo Li, Wenhai Huang, Juan Yang, Jianfeng Wang, Min Hu,





To appear in: European Journal of Pharmaceutical Sciences
Received date: 29 December 2017
Revised date: 11 March 2018
Accepted date: 1 April 2018
Please cite this article as: Qingguo Li, Wenhai Huang, Juan Yang, Jianfeng Wang, Min
Hu, Jianmei Mo, Yuzhu Cheng, Zhanlun Ou, Zhenyu Jason Zhang, Shixia Guan , Gastric
retention pellets of edaravone with enhanced oral bioavailability: Absorption mechanism,
development, and in vitro/in vivo evaluation. The address for the corresponding author
was captured as affiliation for all authors. Please check if appropriate. Phasci(2017),
doi:10.1016/j.ejps.2018.04.002
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may












Gastric retention pellets of edaravone with enhanced oral 
bioavailability: absorption mechanism, development, and in 
vitro/in vivo evaluation 
, , , , , , 








































































































































































































































































































Amemiya S., Kamiya T., Nito C., Inaba T., Kato K., Ueda M., Shimazaki K., Katayama Y., 2005. Anti-
apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur. J. 
Pharmacol. 516, 125-130. 
Avdeef A., Box K.J., Comer J., Hibbert C., Tam K.Y., 1998. pH-metric logP 10. Determination of 
liposomal membrane-water partition coefficients of ionizable drugs. Pharm. Res.-Dordr. 15, 209-215. 
Bala V., Rao S., Bateman E., Keefe D., Wang S., Prestidge C.A., 2016. Enabling oral SN38-based 
chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery system. Mol. 
Pharmaceut. 13, 3518-3525. 
Bardonnet P.L., Faivre V., Pugh W.J., Piffaretti J.C., Falson F., 2006. Gastroretentive dosage forms: 
overview and special case of Helicobacter pylori. J. Control. Release. 111, 1-18. 
Bera T.K., Iavarone C., Kumar V., Lee S., Lee B., Pastan I., 2002. MRP9, an unusual truncated member 
of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci U S A. 99, 
6997-7002. 
Bera T.K., Lee S., Salvatore G., Lee B., Pastan I., 2001. MRP8, a new member of ABC transporter 
superfamily, identified by EST database mining and gene prediction program, is highly expressed in 
breast cancer. Mol. Med. 7, 509-516. 
Brady J.M., Cherrington N.J., Hartley D.P., Buist S.C., Li N., Klaassen C.D., 2002. Tissue distribution 












Clarke G.M.N.J., 1995. Comparative gastrointestinal transit of pellet systems of varying density. Int. J. 
Pharm. 114, 1-11. 
Dean M., Allikmets R., 2001. Complete characterization of the human ABC gene family. J. Bioenerg. 
Biomembr. 33, 475-479. 
Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I., 1987. Expression of a 
multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 84, 265-269. 
Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C., 1996. Relevance of P-glycoprotein for the 
enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 118, 1841-1847. 
Friedman M., Jürgens H.S., 2000. Effect of pH on the stability of plant phenolic compounds. J. Agr. 
Food Chem. 48, 2101-2110. 
Garg R.G.D.G., 2008. Progress in controlled gastroretentive delivery systems. Trop. J. Pharm. Res. 7, 
1055-1066. 
Gillet J., Efferth T., Remacle J., 2007. Chemotherapy-induced resistance by ATP-binding cassette 
transporter genes. Bba.-Rev. Cancer. 1775, 237-262. 
Hidalgo I.J., 2001. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 1, 385-401. 
Higashi Y., Jitsuiki D., Chayama K., Yoshizumi M., 2006. Edaravone (3-methyl-1-phenyl-2-pyrazolin-
5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Pat Cardiovasc 
Drug Discov. 1, 85-93. 
Hoffman A., Stepensky D., Lavy E., Eyal S., Klausner E., Friedman M., 2004. Pharmacokinetic and 
pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm. 277, 141-153. 
Iseki K., Hirano T., Fukushi Y., Kitamura Y., Miyazaki S., Takada M., Sugawara M., Saitoh H., 












vesicles. J. Pharm. Pharmacol. 44, 722-726. 
Keppler D., 2011. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and 
drug therapy. Handb Exp Pharmacol., 299-323. 
Nakayama A., Saitoh H., Oda M., Takada M., Aungst B.J., 2000. Region-dependent disappearance of 
vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur. 
J. Pharm. Sci. 11, 317-324. 
Ono N., Van der Heijden I., Scheffer G.L., Van de Wetering K., Van Deemter E., De Haas M., Boerke 
A., Gadella B.M., De Rooij D.G., Neefjes J.J., Groothuis T.A.M., Oomen L., Brocks L., Ishikawa T., 
Borst P., 2007. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. 
Biochem. J. 406, 31-40. 
Otomo E., Tohgi H., Kogure K., Hirai S., Takakura K., Terashi A., Gotoh F., Maruyama S., Tazaki Y., 
Shinohara Y., Ito E., Sawada T., Yamaguchi T., Kikuchi H., Kobayashi S., Fujishima M., Nakashima 
M., 2003. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction - 
Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 15, 222-229. 
Ottiger C., Wunderli-Allenspach H., 1997. Partition behaviour of acids and bases in a 
phosphatidylcholine liposome-buffer equilibrium dialysis system. Eur. J. Pharm. Sci. 5, 223-231. 
Palm K., Luthman K., Ros J., Grasjo J., Artursson P., 1999. Effect of molecular charge on intestinal 
epithelial drug transport: pH-dependent transport of cationic drugs. J. Pharmacol. Exp. Ther. 291, 435-
443. 
Parikh A., Kathawala K., Tan C.C., Garg S., Zhou X., 2016. Development of a novel oral delivery system 
of edaravone for enhancing bioavailability. Int. J. Pharmaceut. 515, 490-500. 












development, optimization, characterization and in vitro/in vivo evaluation. Drug Deliv. 24, 962-978. 
Robinson K., Mock C., Liang D., 2015. Pre-formulation studies of resveratrol. Drug Dev. Ind. Pharm. 
41, 1464-1469. 
Rong W., Lu Y., Tao Q., Guo M., Lu Y., Ren Y., Yu S., 2014. Hydroxypropyl-Sulfobutyl-beta-
Cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of 
enterocytes. J. Pharm. Sci.-US. 103, 730-742. 
Ruetz S., Gros P., 1994. Phosphatidylcholine translocase - a physiological-role for the MDR2 gene. Cell. 
77, 1071-1081. 
Sano H., Kamijo T., Ino T., Okamoto M., 2010. Edaravone, a free radical scavenger, in the treatment of 
idiopathic sudden sensorineural hearing loss with profound hearing loss. Auris Nasus Larynx. 37, 42-46. 
Sato T., Mizuno K., Ishii F., 2009. A novel administration route for edaravone: I. Effects of metabolic 
inhibitors on skin permeability of edaravone. Int. J. Pharmaceut. 372, 33-38. 
Sato T., Mizuno K., Ishii F., 2010. A novel administration route of edaravone - II: Mucosal absorption 
of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including l-cysteine 
and sodium hydrogen sulfite. Pharmacology. 85, 88-94. 
Schinkel A.H., Jonker J.W., 2012. Mammalian drug efflux transporters of the ATP binding cassette 
(ABC) family: an overview. Adv. Drug Deliver. Rev. 64, 138-153. 
Singh B.N., Kim K.H., 2000. Floating drug delivery systems: an approach to oral controlled drug delivery 
via gastric retention. J. Control. Release. 63, 235-259. 
Sodani K., Patel A., Kathawala R.J., Chen Z.S., 2012. Multidrug resistance associated proteins in 
multidrug resistance. Chin J Cancer. 31, 58-72. 












Deliver. Rev. 61, 287-289. 
Tai C.Y., Jackson M.J., 1981. Weak-acid transport in the small intestine: discrimination in the lamina 
propria. J Membr Biol. 59, 35-43. 
van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., van Meer G., 1996. MDR1 
P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically 
translocates phosphatidylcholine. Cell. 87, 507-517. 
Wacher V.J., Salphati L., Benet L.Z., 2001. Active secretion and enterocytic drug metabolism barriers 
to drug absorption. Adv. Drug Deliver. Rev. 46, 89-102. 
Wagner D., Spahn-Langguth H., Hanafy A., Koggel A., Langguth P., 2001. Intestinal drug efflux: 
formulation and food effects. Adv Drug Deliv Rev. 50 Suppl 1, S13-S31. 
Watanabe T., Tahara M., Todo S., 2008. The novel antioxidant edaravone: from bench to bedside. 
Cardiovasc. Ther. 26, 101-114. 
Yoshida H., Yanai H., Namiki Y., Fukatsu-Sasaki K., Furutani N., Tada N., 2006. Neuroprotective 
effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Reviews. 12, 
9-20. 
Zhang N., Komine-Kobayashi M., Tanaka R., Liu M., Mizuno Y., Urabe T., 2005. Edaravone reduces 
early accumulation of oxidative products and sequential inflammatory responses after transient focal 
ischemia in mice brain. Stroke. 36, 2220-2225. 
Zhang W., Parniak M.A., Mitsuya H., Sarafianos S.G., Graebing P.W., Rohan L.C., 2013. Preformulation 
studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention. Drug Dev. Ind. 
Pharm. 40, 1101-1111. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Graphical abstract 
 
 
ACCEPTED MANUSCRIPT
